Latest Press Releases

New £2.5 m Cornerstone Investor Identified and Agreement Reached to Defer Maturity of $8m Bond to July 2021

Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, today provides a business update following the publication of the Company’s interim results on 31 March 2016 (“Interim Results”).

7th Jun 2016

Read Full ReleaseNew £2.5 m Cornerstone Investor Identified and Agreement Reached to Defer Maturity of $8m Bond to July 2021

Successful Clinical Trial validates use of Genedrive® in Human Genotyping Application

Epistem Holdings Plc (LSE:EHP), the molecular diagnostics, personalised medicine and biotechnology company, today announces the successful completion of an independent clinical trial of its Genedrive® point of care IL28B SNP human genotyping test. The clinical trial was conducted by teams from the Institut Pasteur and Hopital Cochin, Paris in the context of the FP7 funded PoC-HCV project.

3rd May 2016

Read Full ReleaseSuccessful Clinical Trial validates use of Genedrive® in Human Genotyping Application

Epistem Begins Full Commercial Launch for Genedrive® Tuberculosis Tests in India

Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces today that alongside its Indian commercialisation partner, Xcelris Labs, the Company has begun the full commercial launch for its Genedrive® tuberculosis (TB) and antibiotic resistance test.

18th Apr 2016

Read Full ReleaseEpistem Begins Full Commercial Launch for Genedrive® Tuberculosis Tests in India

Copyright 2014 Epistem Holdings Plc